Physician
Nasseri Clinic of Arthritic & Rheumatic Diseases LLC
Nasseri Clinic of Arthritic & Rheumatic Diseases LLC was paid $6.12M by Medicaid between Jan 2018 and Dec 2024, across 47 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 28% of everything it billed.
33Billing provider infoNASSERI CLINIC OF ARTHRITIC & RHEUMATIC DISEASES LLC
CATONSVILLE, MD 21228
CATONSVILLE, MD 21228
33aNPI1821286766assigned 10/04/2007
33bProvider typeInternal Medicine Physician
28Total paid$6.12M
24GClaims115,998
24DCodes billed47
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Internal Medicine Physician providers in Maryland
Rank by total paid#6 of 501
Median peer was paid$77K
This provider vs. median80×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 5,650 | $183K | |
| 2019 | 6,079 | $221K | |
| 2020 | 20,695 | $846K | |
| 2021 | 18,147 | $885K | |
| 2022 | 22,921 | $1.22M | |
| 2023 | 23,191 | $1.63M | |
| 2024incomplete | 19,315 | $1.13M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 28% | 21,883 | 19,862 | $1.71M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 24% | 8,289 | 7,192 | $1.44M |
| 36415 | Collection of venous blood by venipuncture | 16% | 12,275 | 11,282 | $1.00M |
| 96415 | 9.9% | 539 | 418 | $605K | |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 4.8% | 5,830 | 5,300 | $297K |
| 76881 | 2.7% | 2,036 | 1,880 | $166K | |
| 20611 | 2.1% | 2,600 | 1,933 | $129K | |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 2.1% | 1,577 | 1,421 | $126K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 1.7% | 1,020 | 930 | $107K |
| 80053 | Comprehensive metabolic panel | 1.4% | 12,750 | 11,891 | $87K |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | 1.1% | 458 | 228 | $67K |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 1.0% | 992 | 837 | $64K |
35 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.0% | 12,640 | $63K |
| 86140 | <1% | 12,446 | $43K | |
| 86235 | <1% | 230 | $27K | |
| 85652 | <1% | 12,287 | $22K | |
| 86146 | <1% | 229 | $16K | |
| 86147 | <1% | 229 | $16K | |
| 86225 | <1% | 1,286 | $14K | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 224 | $12K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 82 | $12K |
| 86160 | <1% | 898 | $11K | |
| 80074 | <1% | 347 | $11K | |
| 76882 | <1% | 455 | $10K | |
| 86480 | <1% | 202 | $9K | |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | <1% | 996 | $8K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 34 | $7K |
| 83516 | <1% | 306 | $6K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 269 | $4K |
| 86200 | <1% | 291 | $3K | |
| 86376 | <1% | 214 | $3K | |
| 86800 | <1% | 215 | $2K | |
| 86038 | <1% | 214 | $2K | |
| 99243 | <1% | 15 | $2K | |
| 86226 | <1% | 216 | $2K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 121 | $2K |
| 82550 | <1% | 275 | $2K | |
| 86431 | <1% | 317 | $2K | |
| 73630 | <1% | 85 | $1K | |
| 73130 | <1% | 107 | $1K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 12 | $1K |
| 84439 | <1% | 105 | $855.48 | |
| 81003 | <1% | 100 | $187.21 | |
| 84550 | <1% | 43 | $135.16 | |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 0% | 14 | $0.00 |
| J0490 | Injection, belimumab, 10 mg | 0% | 39 | $0.00 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 206 | $-3.65 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialNASSERI, NASSER (PRESIDENT)